Understanding how common fatty liver disease is in patients with acute heart issues
The Prevalence of Non-Alcoholic Fatty Liver Disease in Patients With an Acute Cardiac Event Followed at Ziekenhuis Oost-Limburg, Genk, Belgium
This study is trying to find out how many patients with heart problems also have fatty liver disease to help improve their treatment and care.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 1000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Ziekenhuis Oost-Limburg Academic / other |
| Locations | 1 site (Genk, Limburg) |
| Trial ID | NCT05378321 on ClinicalTrials.gov |
What this trial studies
This study aims to investigate the prevalence of non-alcoholic fatty liver disease (NAFLD) in patients experiencing acute coronary syndrome (ACS). By utilizing non-invasive diagnostic testing, the research will gather data on how many ACS patients also have NAFLD, a condition that may impact cardiovascular disease risk. This is particularly important as there is currently a lack of data on this relationship in Belgium, which could inform better management strategies for these patients. The findings could lead to improved long-term clinical outcomes for individuals with both conditions.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old who are currently experiencing acute coronary syndrome and can understand Dutch.
Not a fit: Patients with excessive alcohol abuse, other liver diseases, or secondary causes of steatosis may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the understanding of cardiovascular risks associated with NAFLD, leading to better management and treatment options for affected patients.
How similar studies have performed: While there is limited research on the prevalence of NAFLD in CVD patients, studies have shown that understanding this relationship is crucial, indicating potential for significant findings.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * \>18 years * having acute cardiovascular syndrome * able to understand Dutch * able to understand the informed consent Exclusion Criteria: * excessive alcohol abuse * other liver disease * secondary causes of steatosis
Where this trial is running
Genk, Limburg
- Ziekenhuis Oost-Limburg — Genk, Limburg, Belgium (Recruiting)
Study contacts
- Study coordinator: Geert Robaeys, Phd. MD.
- Email: geert.robaeys@zol.be
- Phone: 089 32 65 05
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.